Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer
DDR alterations were not associated with outcomes following LuPSMA. This has implications for treatment sequencing in mCRPC, particularly in patients with DDR alterations.
Authors
- Hailey Stoltenberg
- Narmeen S Rashid (ORCID: https://orcid.org/0000-0003-2321-2711)
- Jolivette Ritzer
- Mary‐Ellen Taplin (ORCID: https://orcid.org/0000-0002-3384-0300)
- Avina Rami (ORCID: https://orcid.org/0000-0002-5509-6033)
- Praful Ravi (ORCID: https://orcid.org/0000-0002-7466-4702)
- Andrew Wolanski
- Heather A. Jacene (ORCID: https://orcid.org/0000-0001-7167-078X)
- Wanling Xie (ORCID: https://orcid.org/0000-0001-5995-8000)
- Ashutosh Tewari (ORCID: https://orcid.org/0000-0002-3146-4524)
- Atish D. Choudhury (ORCID: https://orcid.org/0000-0001-9344-6631)
- Caiyun Zhong
- Emily Wheeler
Institutions
- Dana-Farber Cancer Institute (US)
- Dana-Farber/Harvard Cancer Center (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1016/j.esmoop.2024.104131
- Citations
- 3
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- American Society of Clinical Oncology
- Dana-Farber Cancer Institute